Key result
FlagT4Gv vaccine provided complete sterile immunity and 100% survival against virulent classical swine fever virus challenge as early as 3 days post-vaccination in swine.
Why the study?
Does FlagT4Gv vaccine protect swine against virulent classical swine fever virus challenge at early time points?
Does FlagT4Gv vaccine protect swine against virulent classical swine fever virus challenge at early time points?
FlagT4Gv provides rapid and sterile immunity against classical swine fever virus as early as 3 days post-vaccination in swine, potentially mediated by early IFN-α induction.
Supports rapid-onset vaccine potential in swine; leaves open field efficacy, safety, and regulatory translation pending further studies.
Prophylactic vaccination using live attenuated classical swine fever (CSF) vaccines has been a very effective method to control the disease in endemic regions and during outbreaks in previously disease-free areas. These vaccines confer effective protection against the disease at early times post-vaccination although the mechanisms mediating the protection are poorly characterized. Here we present the events occurring after the administration of our in-house developed live attenuated marker vaccine, FlagT4Gv. We previously reported that FlagT4Gv intramuscular (IM) administered conferred effective protection against intranasal challenge with virulent CSFV (BICv) as early as 7 days post-vaccination. Here we report that FlagT4Gv is able to induce protection against disease as early as three days post-vaccination. Immunohistochemical testing of tissues from FlagT4Gv-inoculated animals showed that tonsils were colonized by the vaccine virus by day 3 post-inoculation. There was a complete absence of BICv in tonsils of FlagT4Gv-inoculated animals which had been intranasal (IN) challenged with BICv 3 days after FlagT4Gv infection, confirming that FlagT4Gv inoculation confers sterile immunity. Analysis of systemic levels of 19 different cytokines in vaccinated animals demonstrated an increase of IFN-α three days after FlagT4Gv inoculation compared with mock infected controls.
No takes yet. Share an insight, caveat, or question.
Holinka et al. (2017) studied Classical swine fever (n=41). FlagT4Gv vaccine vs. Mock vaccination was evaluated on Survival and protection against clinical disease after virulent BICv challenge. FlagT4Gv vaccine provided complete sterile immunity and 100% survival against virulent classical swine fever virus challenge as early as 3 days post-vaccination in swine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: